CRBP - Corbus Pharmaceuticals Holdings, Inc. Stock Price and Quote

CRBP [NASD]

Corbus Pharmaceuticals Holdings, Inc.

Index	-	P/E	-	EPS (ttm)	-10.15	Insider Own	0.30%	Shs Outstand	4.16M	Perf Week	6.13%
Market Cap	28.57M	Forward P/E	-	EPS next Y	-53.22	Insider Trans	0.00%	Shs Float	4.15M	Perf Month	146.44%
Income	-42.30M	PEG	-	EPS next Q	-4.09	Inst Own	19.00%	Short Float / Ratio	3.52% / 0.33	Perf Quarter	118.12%
Sales	0.00M	P/S	-	EPS this Y	8.80%	Inst Trans	-91.93%	Short Interest	0.15M	Perf Half Y	38.63%
Book/sh	7.94	P/B	0.92	EPS next Y	9.70%	ROA	-53.30%	Target Price	120.00	Perf Year	-52.65%
Cash/sh	15.06	P/C	0.48	EPS next 5Y	-	ROE	-91.30%	52W Range	2.11 - 16.66	Perf YTD	119.31%
Dividend	-	P/FCF	-	EPS past 5Y	12.10%	ROI	-	52W High	-56.36%	Beta	2.11
Dividend %	-	Quick Ratio	4.80	Sales past 5Y	-	Gross Margin	-	52W Low	244.55%	ATR	0.95
Employees	33	Current Ratio	4.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	63.41	Volatility	16.44% 22.04%
Optionable	Yes	Debt/Eq	0.58	EPS Q/Q	-6.50%	Profit Margin	-	Rel Volume	0.78	Prev Close	8.83
Shortable	Yes	LT Debt/Eq	0.48	Earnings	Mar 07 BMO	Payout	-	Avg Volume	445.46K	Price	7.27
Recom	2.50	SMA20	45.33%	SMA50	66.12%	SMA200	38.06%	Volume	348,907	Change	-17.67%

Sep-08-20

Downgrade

ROTH Capital

Buy → Neutral

$40 → $3

Sep-08-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Sep-08-20

Downgrade

Jefferies

Buy → Hold

$18 → $2.50

Sep-08-20

Downgrade

BTIG Research

Buy → Neutral

Jul-07-20

Initiated

ROTH Capital

Buy

$40

Jun-17-20

Initiated

BTIG Research

Buy

$22

Mar-26-20

Initiated

Nomura

Buy

$12

Apr-05-19

Initiated

Jefferies

Buy

Mar-20-19

Initiated

Oppenheimer

Outperform

$28

Jan-11-19

Reiterated

Cantor Fitzgerald

Overweight

$36 → $38

Show Previous Ratings

Mar-14-23 04:35PM	Corbus Pharmaceuticals Data on CRB-601 av8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting PR Newswire +36.44%
Mar-07-23 08:00AM	Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update PR Newswire -6.67%
Mar-06-23 08:00AM	Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA PR Newswire
Mar-02-23 08:00AM	Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire +5.36%
Feb-13-23 11:27AM	Corbus Pharma Expands Precision Oncology Pipeline With Addition Of Clinical-Stage Antibody Drug Conjugate Benzinga -11.06%
06:55AM	Loading…
06:55AM	Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire
Nov-10-22 09:05AM	Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting PR Newswire
Nov-08-22 08:05AM	Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
Nov-03-22 05:00PM	15 Best High Volume Penny Stocks to Buy Now Insider Monkey
Oct-14-22 08:05AM	Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting PR Newswire -9.50%
Sep-26-22 08:05AM	Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors PR Newswire -6.38%
Sep-22-22 08:00AM	Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference PR Newswire
Sep-12-22 07:00AM	Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
Aug-09-22 09:25AM	Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates Zacks
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
08:00AM	Loading…
May-11-22 08:00AM	Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference PR Newswire -8.18%
May-10-22 09:25AM	Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
Apr-08-22 01:05PM	Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire -5.26%
Mar-31-22 09:51AM	Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study Zacks
Mar-18-22 10:12AM	Zacks.com featured highlights include Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals Zacks -22.78%
Mar-17-22 10:41AM	Ride on Rising P/E Investing With These 5 Top-Ranked Stocks Zacks
Mar-11-22 08:05AM	Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference PR Newswire +5.00%
Mar-08-22 06:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates Zacks +7.06%
08:05AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates PR Newswire
Mar-02-22 07:00AM	Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer GlobeNewswire +11.59%
Jan-14-22 09:38AM	Investors Financial Group, LLC Buys USHG Acquisition Corp, Daktronics Inc, Weber Inc, Sells MP ... GuruFocus.com
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th ACCESSWIRE -6.95%
Dec-31-21 09:58AM	Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now Zacks
Dec-29-21 10:00AM	After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) Zacks
10:00AM	Loading…
Dec-07-21 10:00AM	Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP) Zacks +5.54%
08:05AM	Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer PR Newswire
Nov-12-21 08:05AM	Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates PR Newswire
Nov-11-21 08:05AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference PR Newswire
Nov-02-21 03:02PM	Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-21-21 09:30AM	uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors GlobeNewswire
Sep-10-21 06:45AM	Could The Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Ownership Structure Tell Us Something Useful? Simply Wall St.
Aug-12-21 09:45AM	Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates Zacks -5.26%
08:05AM	Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates GlobeNewswire
Jul-29-21 03:04PM	Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -5.41%
Jun-24-21 08:05AM	Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis GlobeNewswire
Jun-21-21 05:48PM	Is Corbus Pharmaceuticals Holdings Inc (CRBP) A Good Stock To Buy? Insider Monkey
Jun-18-21 08:38AM	Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Jun-12-21 04:19AM	We Think Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package Needs To Be Put Under A Microscope Simply Wall St.
Jun-03-21 02:42AM	Does Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Have A Healthy Balance Sheet? Simply Wall St.
Jun-02-21 06:19AM	This Biotech Penny Stock Is Better Than Dogecoin Motley Fool
Jun-01-21 12:26PM	Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings Benzinga -5.53%
07:05AM	Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases GlobeNewswire
May-25-21 08:05AM	Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress GlobeNewswire +5.33%
May-19-21 09:20AM	CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING GlobeNewswire
May-17-21 08:34AM	Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't? Zacks
May-11-21 08:05AM	Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences GlobeNewswire
May-03-21 03:01PM	Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-20-21 08:05AM	Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) GlobeNewswire
Mar-30-21 08:05AM	Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis GlobeNewswire
Mar-18-21 12:00PM	Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade Zacks
Mar-15-21 02:30PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q4 2020 Earnings Call Transcript Motley Fool
08:26AM	Recap: Corbus Pharmaceuticals Q4 Earnings Benzinga
07:05AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results GlobeNewswire
06:30AM	Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-10-21 12:59AM	Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares? Simply Wall St.
Mar-09-21 08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire +11.83%
Mar-08-21 08:05AM	Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021 GlobeNewswire
Mar-04-21 12:30PM	Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks -15.32%
Feb-11-21 11:29AM	GW Deal With Jazz Spurs Pot Stock Wave, a Look at Smaller Players Market Exclusive
Feb-02-21 10:44AM	ROCE Insights For Corbus Pharmaceuticals Benzinga +15.70%
10:05AM	Cannabis ETF Tops in January: 5 Stocks That Led the Way Zacks
Jan-20-21 08:05AM	Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases GlobeNewswire
Jan-14-21 08:30AM	Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3% Zacks +8.07%
Jan-12-21 08:49AM	Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options Zacks
Jan-09-21 02:16AM	A Look At Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Share Price Returns Simply Wall St.
Dec-07-20 10:43PM	Is CRBP A Good Stock To Buy Now? Insider Monkey
Dec-04-20 08:44AM	Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock? Zacks +6.77%
Dec-01-20 10:28AM	Looking Into Corbus Pharmaceuticals's Return On Capital Employed Benzinga +18.85%
Nov-16-20 09:54AM	ROCE Insights For Corbus Pharmaceuticals Benzinga
Nov-12-20 08:05AM	Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +13.11%
Nov-11-20 10:00AM	Corbus Pharma Drops 6% On 3Q Miss; Street Sees 79% Upside SmarterAnalyst
Nov-10-20 03:31PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q3 2020 Earnings Call Transcript Motley Fool
08:55AM	Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:32AM	Corbus Pharmaceuticals: Q3 Earnings Insights Benzinga
07:05AM	Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates GlobeNewswire
Nov-09-20 10:27AM	Corbus Pharmaceuticals's Earnings: A Preview Benzinga +7.96%
08:05AM	Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis GlobeNewswire
Nov-03-20 08:05AM	Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020 GlobeNewswire
Oct-29-20 12:35PM	Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-23-20 08:05AM	Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020 GlobeNewswire
Oct-21-20 08:05AM	Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020 GlobeNewswire
Oct-08-20 08:05AM	Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates GlobeNewswire
Oct-07-20 10:46AM	Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint Zacks
Oct-06-20 07:05AM	Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint GlobeNewswire -35.98%
Oct-04-20 09:46AM	How Much Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Do Institutions Own? Simply Wall St.
Sep-25-20 08:53AM	Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock? Zacks
Sep-24-20 09:54AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga
Sep-10-20 10:01AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga -6.97%
Sep-08-20 10:00AM	Why Corbus Pharmaceuticals Is Getting Slammed Today Motley Fool -75.89%
07:05AM	Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis GlobeNewswire
Sep-04-20 09:40AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga
Aug-25-20 09:19AM	Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options Zacks
Aug-24-20 06:30AM	2 Dirt-Cheap Robinhood Stocks That Could Skyrocket Motley Fool
Aug-20-20 10:17AM	Are Insiders Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock? Simply Wall St. +5.45%

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moran Sean F.	Chief Financial Officer	Aug 10	Buy	0.26	20,000	5,198	199,272	Aug 10 10:16 AM
Millian Craig Stuart	Chief Operating Officer	Aug 10	Buy	0.25	5,000	1,272	27,000	Aug 12 09:43 AM
Cohen Yuval	Chief Executive Officer	Aug 10	Buy	0.26	3,800	1,003	98,230	Aug 11 09:55 AM
Moran Sean F.	Chief Financial Officer	May 16	Buy	0.30	12,000	3,600	179,272	May 16 11:03 AM
Cohen Yuval	Chief Executive Officer	May 16	Buy	0.25	10,500	2,625	94,430	May 16 10:41 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience